We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Molecular Profiles and Onyx Scientific Form Strategic Alliance

News   Aug 14, 2012

 
Molecular Profiles and Onyx Scientific Form Strategic Alliance
 
 
 

RELATED ARTICLES

“Smart Drug” Shows Promise for Metastatic Triple-Negative Breast Cancer

News

A new "smart drug" has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial at NewYork-Presbyterian/Columbia's Herbert Irving Comprehensive Cancer Center and other centers.

READ MORE

Drug Combo Could Become New Standard Treatment for Advanced Kidney Cancer

News

A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a Phase 3 clinical trial.

READ MORE

Antidepressant Based on Ketamine Gets Backing From FDA Advisory Group

News

A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE